摘要
Objective To provide reference for strengthening the management of preventing interest conflicts among pharmacopoeia members.Methods The procedures of the United States Pharmacopoeia (USP) Committee,and the actions taken by members or experts of US food and drug administration to prevent interest conflicts were referred to analyze the problems in the management of preventing interest conflicts in China pharmacopoeia committee,and corresponding suggestions were put forward.Results and Conclusion Although the interest and risk avoidance system and dismissal measures were mentioned in the measures for the administration of Chinese pharmacopoeia commissioners,no detailed rules and specific procedures were formulated to prevent interest conflicts of Chinese pharmacopoeia commissioners.It is suggested that preventing the interest conflicts of pharmacopoeia members should be included into the drug formulation and revision system as soon as possible.In addition,the management measures for pharmacopoeia members should be further perfected to avoid the interest conflicts.The scope of publicity for the formulation and revision of drug standards should be expanded and the supervision and implementation must be strengthened.Therefore,the members of pharmacopoeia can participate in the formulation and revision of drug standards in a fair or just manner.
